In June 2024, a landmark Alzheimer's research paper was retracted due to fraud allegations. Did we waste billions of dollars and thousands of hours of scientists’ time? Maybe not. There are now two potentially helpful drugs on the market targeting the subject of the paper: amyloid beta. This video breaks down the amyloid-beta hypothesis, the fraud itself and where we go from here.
Sources:
- Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
- APOE gene
- The discovery of Alzheimer's disease
- What Happens to the Brain in Alzheimer's Disease?
- Mouse Models of Alzheimer’s Disease
- Alzheimer’s blood test performs as well as FDA-approved spinal fluid tests
- Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
- Unlocking how the new Alzheimer’s drug lecanemab works
- Lecanemab in Early Alzheimer’s Disease
- Amyloid Beta Peptide
- Researchers plan to retract landmark Alzheimer’s paper containing doctored images
- Faked Beta-Amyloid Data. What Does It Mean?
- A specific amyloid-?? protein assembly in the brain impairs memory
